Trials / Completed
CompletedNCT03657602
Immediate Postpartum Insertion of Contraceptive Intrauterine Devices
Immediate Postpartum Insertion of Kyleena vs Mirena Contraceptive Intrauterine Devices
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- University of Oklahoma · Academic / Other
- Sex
- Female
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
In this randomized trial, investigators intend to determine the expulsion and discontinuation rate of immediate postpartum intrauterine devices in the patient population of the University of Oklahoma Women's Healthcare Specialists Clinic (OUWHSC).
Detailed description
Between 40-57% of women report having unprotected intercourse prior to the 6 week postpartum visit. Immediate postpartum long-acting reversible contraception (LARC) is extremely important in preventing short-interval and unintended pregnancies. The postpartum period is an excellent time for intrauterine device (IUD) or implant insertion as women are often highly motivated to prevent unwanted pregnancies at this time. Per the American College of Obstetrics and Gynecology (ACOG), expulsion rates for immediate postpartum IUD insertion are higher than for interval or post-abortion insertion. Despite the higher expulsion rate of immediate postpartum IUD placement over interval placement, cost-benefit analysis data strongly suggest the superiority of immediate placement in reduction of unintended pregnancy, especially for women at greatest risk of not attending the postpartum follow-up visit. This study will randomly allocate participants one to one to the Kyleena or the Mirena IUD group, and participants will be blinded to allocation of groups. Participants will follow up at routine postpartum visit within 4 weeks of delivery, and a second follow up will be performed at 10 weeks. Ultimately, this study will attempt to provide more detailed information on the difference of rates of expulsion and discontinuation of the different-sized Mirena and Kyleena intrauterine devices.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kyleena Intrauterine System | Participant will be randomly allocated to this intervention |
| DRUG | Mirena Intrauterine System | Participant will be randomly allocated to this intervention |
Timeline
- Start date
- 2019-12-15
- Primary completion
- 2023-01-15
- Completion
- 2023-01-15
- First posted
- 2018-09-05
- Last updated
- 2023-04-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03657602. Inclusion in this directory is not an endorsement.